China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma executives. But to Roivant…

When a spray-dried formulation falls short, whether due to poor bioavailability, scale-up limitations, or high pill burden, the path forward…

After its bet on a rare eye disease gene therapy ended in a phase 3 fail last year, Johnson &…

Storm Therapeutics has closed a $56 million series C financing as the British biotech kicks off a phase 2 sarcoma…

In the evolving landscape of vaccine technology, mRNA and lipid nanoparticle (LNP) platforms have revolutionized our approach to immunization, particularly…

In a groundbreaking study published in Cell Research, a team of scientists led by Cheng, Zhou, and Huang have unveiled…

Aligos Therapeutics has secured a $25 million cash infusion in return for selling the China rights to its phase 2-stage…

In the ever-evolving landscape of medical research, predicting cardiovascular risk in patients with type 1 diabetes has remained a formidable…

Ancient DNA research has revolutionized our understanding of human population history, revealing intricate patterns of migration, admixture, and demographic change.…

In a groundbreaking advancement for neuroscience, researchers have unveiled a sophisticated model that deciphers the intricate relationship between neural activity…